IP Library › Granted Patent US 12702698
Granted Patent B2
US 12702698 · App. 18/226,405 · Granted Aug 11, 2026

GLP-1 compositions and uses thereof

Inventors: Eva Horn Moeller (Alleroed, DK); Michael Duelund Soerensen (Soeborg, DK); Joakim Lundqvist (Malmoe, SE)
Assignee: Novo Nordisk A/S
A61K38/26A61K9/0019A61K9/08A61K47/02A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12702698
App. No.
18/226,405
Granted
Aug 11, 2026
Kind
B2
Abstract

The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.

Claims (26)

1 . A liquid pharmaceutical composition comprising:

semaglutide;

wherein said composition

(a) does not contain phenol; and

(b) is for subcutaneous administration; and

(c) (i) is an aqueous solution comprising at least 60% (w/w) water or (ii) further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of a buffer or an isotonic agent; and

wherein the semaglutide is in the range of 0.50 mg/mL −3.2 mg/mL; and

wherein the pH of the composition is about 7.4.

2 . A method of treating diabetes comprising administering to a subject in need of such method a therapeutically effective amount of the liquid pharmaceutical composition according to claim 1 .

3 . A method of treating obesity comprising administering to a subject in need of such method a therapeutically effective amount of the liquid pharmaceutical composition according to claim 1 .

4 . The liquid pharmaceutical composition of claim 1 , wherein the semaglutide is 0.5 mg/mL.

5 . The liquid pharmaceutical composition of claim 1 , wherein the semaglutide is 1.0 mg/mL.

6 . The liquid pharmaceutical composition of claim 1 , wherein the semaglutide is 1.7 mg/0.75 mL.

7 . The liquid pharmaceutical composition of claim 1 , where in the semaglutide is 2.0 mg/mL.

8 . The liquid pharmaceutical composition of claim 1 , wherein the semaglutide is 3.2 mg/mL.

9 . The liquid pharmaceutical composition of claim 1 , wherein the buffer comprises disodiumhydrogenphosphate dihydrate or trisodiumcitrate dihydrate.

10 . The liquid pharmaceutical composition of claim 9 , wherein the disodiumhydrogenphosphate dihydrate is 1.42 mg/mL.

11 . The liquid pharmaceutical composition of claim 9 , wherein the trisodiumcitrate dihydrate is 2.35 mg/mL.

12 . The liquid pharmaceutical composition of claim 1 , wherein the isotonic agent is propylene glycol or sodium chloride.

13 . The liquid pharmaceutical composition of claim 12 , wherein the propylene glycol is 14 mg/mL.

14 . The liquid pharmaceutical composition of claim 12 , wherein the sodium chloride is 8.25 mg/mL.

15 . The liquid pharmaceutical composition of claim 12 , wherein the sodium chloride is 6.3 mg/mL.

16 . The liquid pharmaceutical composition of claim 1 , further comprising one or more pharmaceutically acceptable excipients to adjust the pH.

17 . The liquid pharmaceutical composition of claim 16 , wherein the one or more pharmaceutically acceptable excipients comprise hydrochloric acid or sodium hydroxide.

18 . The liquid pharmaceutical composition of claim 16 , wherein the one or more pharmaceutically acceptable excipients comprise hydrochloric acid and sodium hydroxide.

19 . The liquid pharmaceutical composition of claim 1 , wherein said liquid pharmaceutical composition comprises no preservative.